Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 5 (May)

1. Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell.
   Oncogene, 27(20): 2858-67. [Abstract] [Full-text]
2. Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer.
   Oncogene, 27(20): 2877-85. [Abstract] [Full-text]
3. Phospholipase C gamma 1 regulates the Rap GEF1-Rap1 signalling axis in the control of human prostate carcinoma cell adhesion.
   Oncogene, 27(20): 2823-32. [Abstract] [Full-text]
4. Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis.
   Oncogene, 27(20): 2868-76. [Abstract] [Full-text]
5. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
   Lancet Oncol, 9(5): 445-52. [Abstract] [Full-text]
6. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling.
   FASEB J, 22(5): 1512-20. [Abstract] [Full-text]
7. Does the level of prostate cancer risk affect cancer prevention with finasteride?
   Urology, 71(5): 854-7. [Abstract] [Full-text]
8. Focal cryoablation of prostate: a review.
   ScientificWorldJournal, 8: 486-91. [Abstract] [Full-text]
9. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition.
   Br J Cancer, 98(9): 1574-81. [Abstract] [Full-text]
10. Mortality after urologic cancer surgery: impact of non-index case volume.
    Urology, 71(5): 906-10. [Abstract] [Full-text]
11. Factors predicting for formation of bladder outlet obstruction after high-intensity focused ultrasound in treatment of localized prostate cancer.
    Urology, 71(5): 863-7. [Abstract] [Full-text]
12. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
    Urology, 71(5): 933-7. [Abstract] [Full-text]
13. Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.
    Urology, 71(5): 947-51. [Abstract] [Full-text]
14. Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
    Urology, 71(5): 938-41. [Abstract] [Full-text]
15. Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.
    Urology, 71(5): 942-6. [Abstract] [Full-text]
16. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
    Urology, 71(5): 787-91. [Abstract] [Full-text]
17. Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial.
    Urology, 71(5): 967-70. [Abstract] [Full-text]
18. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.
    Cancer, 112(10): 2195-201. [Abstract] [Full-text]
19. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
    Cancer, 112(10): 2188-94. [Abstract] [Full-text]
20. A comprehensive analysis of transcript signatures of the phosphatidylinositol-3 kinase/protein kinase B signal-transduction pathway in prostate cancer.
    BJU Int, 101(11): 1454-60. [Abstract] [Full-text]
21. Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate.
    Genes Chromosomes Cancer, 47(7): 565-72. [Abstract] [Full-text]
22. Utilization and outcomes of minimally invasive radical prostatectomy.
    J Clin Oncol, 26(14): 2278-84. [Abstract] [Full-text]
23. The heterochromatin protein 1 family is regulated in prostate development and cancer.
    J Urol, 179(6): 2435-9. [Abstract] [Full-text]
24. Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis.
    J Urol, 179(6): 2192-5; discussion 2195-6. [Abstract] [Full-text]
25. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
    J Urol, 179(6): 2181-5; discussion 2185-6. [Abstract] [Full-text]
26. Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles.
    J Urol, 179(6): 2197-201; discussion 2202. [Abstract] [Full-text]
27. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.
    J Urol, 179(6): 2203-6; discussion 2206. [Abstract] [Full-text]
28. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
    J Urol, 179(6): 2187-91; discussion 2191. [Abstract] [Full-text]
29. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories.
    J Urol, 179(6): 2212-6; discussion 2216-7. [Abstract] [Full-text]
30. Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram.
    J Urol, 179(6): 2207-10; discussion 2210-1. [Abstract] [Full-text]
31. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells.
    Biochem Pharmacol, 75(11): 2112-21. [Abstract] [Full-text]
32. Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy.
    Int J Radiat Oncol Biol Phys, 71(2): 611-7. [Abstract] [Full-text]
33. Radiotherapy after prostatectomy: is the evidence for dose escalation out there?
    Int J Radiat Oncol Biol Phys, 71(2): 346-50. [Abstract] [Full-text]
34. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant.
    Int J Radiat Oncol Biol Phys, 71(2): 338-45. [Abstract] [Full-text]
35. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 71(2): 358-61. [Abstract] [Full-text]
36. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Int J Radiat Oncol Biol Phys, 71(2): 330-7. [Abstract] [Full-text]
37. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 71(2): 351-7. [Abstract] [Full-text]
38. Emodin induces apoptosis in human prostate cancer cell LNCaP.
    Asian J Androl, 10(4): 625-34. [Abstract] [Full-text]
39. Mass screening-based case-control study of diet and prostate cancer in Changchun, China.
    Asian J Androl, 10(4): 551-60. [Abstract] [Full-text]
40. Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression.
    Asian J Androl, 10(4): 635-41. [Abstract] [Full-text]
41. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
    Oncogene, 27(22): 3201-10. [Abstract] [Full-text]
42. Cyclin D3 action in androgen receptor regulation and prostate cancer.
    Oncogene, 27(22): 3111-21. [Abstract] [Full-text]
43. Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2.
    J Pharmacol Exp Ther, 325(3): 841-9. [Abstract] [Full-text]
44. LYRIC/AEG-1 overexpression modulates BCCIPalpha protein levels in prostate tumor cells.
    Biochem Biophys Res Commun, 371(2): 333-8. [Abstract] [Full-text]
45. Prostate cancer.
    Lancet, 371(9625): 1710-21. [Abstract] [Full-text]
46. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
    J Clin Oncol, 26(15): 2544-9. [Abstract] [Full-text]
47. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
    J Clin Oncol, 26(15): 2497-504. [Abstract] [Full-text]
48. Calcifications in prostate and ejaculatory system: a study on 298 consecutive whole mount sections of prostate from radical prostatectomy or cystoprostatectomy specimens.
    Ann Diagn Pathol, 12(3): 165-70. [Abstract] [Full-text]
49. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.
    BJU Int, 101(12): 1513-8. [Abstract] [Full-text]
50. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study.
    BJU Int, 101(12): 1519-23. [Abstract] [Full-text]
51. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.
    BJU Int, 101(12): 1507-12. [Abstract] [Full-text]
52. Progression after radical prostatectomy for men in their thirties compared to older men.
    BJU Int, 101(12): 1503-6. [Abstract] [Full-text]
53. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    BJU Int, 101(12): 1497-501. [Abstract] [Full-text]
54. The morbidity of transperineal template-guided prostate mapping biopsy.
    BJU Int, 101(12): 1524-9. [Abstract] [Full-text]
55. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis.
    Prostate, 68(9): 919-23. [Abstract] [Full-text]
56. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.
    Prostate, 68(9): 985-93. [Abstract] [Full-text]
57. Expression profiling of CD133+ and CD133- epithelial cells from human prostate.
    Prostate, 68(9): 1007-24. [Abstract] [Full-text]
58. Clinical assessment of the cancer diagnostic value of prostatic zinc: a comprehensive needle-biopsy study.
    Prostate, 68(9): 994-1006. [Abstract] [Full-text]
59. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
    Prostate, 68(9): 935-44. [Abstract] [Full-text]
60. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells.
    Prostate, 68(9): 924-34. [Abstract] [Full-text]
61. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.
    Prostate, 68(9): 975-84. [Abstract] [Full-text]
62. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
    Prostate, 68(9): 965-74. [Abstract] [Full-text]
63. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
    Prostate, 68(9): 955-64. [Abstract] [Full-text]
64. Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer.
    Oncogene, 27(23): 3313-28. [Abstract] [Full-text]
65. High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.
    Tumour Biol, 29(1): 1-8. [Abstract] [Full-text]
66. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.
    BMC Cancer, 8: 132. [Abstract] [Full-text]
67. Dietary agents for chemoprevention of prostate cancer.
    Cancer Lett, 265(2): 167-76. [Abstract] [Full-text]
68. Diagnostic radiation procedures and risk of prostate cancer.
    Br J Cancer, 98(11): 1852-6. [Abstract] [Full-text]
69. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
    Nat Genet, 40(6): 741-50. [Abstract] [Full-text]
70. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
    Prostate, 68(10): 1116-25. [Abstract] [Full-text]
71. Stem cells: The root of prostate cancer?
    J Cell Physiol, 216(2): 332-6. [Abstract] [Full-text]
72. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.
    Prostate, 68(10): 1097-104. [Abstract] [Full-text]
73. Diabetes mellitus and prostate cancer risk.
    Prostate, 68(10): 1126-32. [Abstract] [Full-text]
74. Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism.
    Prostate, 68(10): 1035-47. [Abstract] [Full-text]
75. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Prostate, 68(10): 1133-42. [Abstract] [Full-text]
76. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.
    Prostate, 68(10): 1105-15. [Abstract] [Full-text]
77. Altered expression of 12S/MT-RNR1, MT-CO2/COX2, and MT-ATP6 mitochondrial genes in prostate cancer.
    Prostate, 68(10): 1086-96. [Abstract] [Full-text]
78. Prediction of lymphatic invasion by peritumoral lymphatic vessel density in prostate biopsy cores.
    Prostate, 68(10): 1057-63. [Abstract] [Full-text]
79. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer.
    Prostate, 68(10): 1048-56. [Abstract] [Full-text]
80. CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells.
    Cancer Sci, 99(7): 1362-9. [Abstract] [Full-text]
81. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate.
    Cancer Sci, 99(7): 1326-33. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.